Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : Science Committee appointment (Form 6-K)

09/23/2021 | 07:12am EDT
Science Committee appointment
AstraZeneca PLC announced today that the Board has appointed Diana Layfield as a member of the Science Committee, with effect from 1 October 2021.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC

Disclaimer

AstraZeneca plc published this content on 23 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 September 2021 11:11:06 UTC.


© Publicnow 2021
All news about ASTRAZENECA PLC
09:42aASTRAZENECA : recommends shareholders reject 'Mini-Tender' Offer by TRC Capital Investment..
PU
09:32aASTRAZENECA : Kepler Cheuvreux maintains a Buy rating
MD
09:28aCORONAVIRUS : About 300,000 additional doses of Covid-19 vaccines for Senegal These additi..
AQ
09:28aCORONAVIRUS : About 300,000 additional doses of Covid-19 vaccines for Senegal
AQ
05:19aASTRAZENECA : EU has exported over 1 bln COVID-19 vaccines, von der Leyen says
RE
04:50aASTRAZENECA : Imfinzi plus tremelimumab significantly improved overall survival in HIMALAY..
AQ
04:49aVALNEVA : To Seek EU Nod For COVID-19 Jab After Outperforming AstraZeneca In Late-Stage Tr..
MT
04:23aSINOVAC BIOTECH : Thailand to cease Sinovac vaccine use when stocks end this month
RE
04:11aASTRAZENECA : Medical Products Supply Chain Week In Review – October 14, 2021
AQ
03:58aVALNEVA : Shares Surge 32% On COVID-19 Jab's Higher Efficacy Than AstraZeneca In Trial
MT
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 584 M - -
Net income 2021 4 915 M - -
Net Debt 2021 24 833 M - -
P/E ratio 2021 34,1x
Yield 2021 2,36%
Capitalization 185 B 185 B -
EV / Sales 2021 5,90x
EV / Sales 2022 4,80x
Nbr of Employees 76 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 119,48 $
Average target price 137,31 $
Spread / Average Target 14,9%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC18.77%187 492
JOHNSON & JOHNSON1.74%424 619
ROCHE HOLDING AG16.59%339 442
NOVO NORDISK A/S54.22%234 792
PFIZER, INC.12.71%232 621
ELI LILLY AND COMPANY41.54%215 657